Roux C, Dougados M
Centre d'Evaluation des Maladies Osseuses, Department of Rheumatologie, Hôpital Cochin, Hopitaux de Paris, Université René Descartes, France.
Drugs. 1999 Nov;58(5):823-30. doi: 10.2165/00003495-199958050-00005.
Paget's disease is a progressive bone disease, monostotic or polyostotic, characterised by hypertrophy of affected bones and accelerated disorganised bone remodelling. It results in bone deformities and pain, with a risk for articular and neurological complications, and fractures. The risk of complications, and thus the therapeutic decision, is a function of the age of the patient, and the severity and the activity of the disease. Bisphosphonates are first-line therapy for Paget's disease, and the advent of the new bisphosphonates permits a dramatic improvement in treatment. The optimal treatment regimen should obtain normalisation or quasi-normalisation of markers of bone remodelling. This result has the potential for a long-term control of the disease.
佩吉特病是一种进行性骨病,可为单骨型或多骨型,其特征是受累骨骼肥大以及骨重建加速且紊乱。它会导致骨骼畸形和疼痛,存在关节和神经并发症以及骨折的风险。并发症的风险以及治疗决策取决于患者的年龄、疾病的严重程度和活动度。双膦酸盐是佩吉特病的一线治疗药物,新型双膦酸盐的出现使治疗有了显著改善。最佳治疗方案应使骨重建标志物恢复正常或接近正常。这一结果有可能实现对该疾病的长期控制。